JET2019

講演情報

Presentation Awards

[L2-9] Presentation Awards

Heat-14 Femoropopliteal, clinical trials

2019年2月23日(土) 14:50 〜 16:20 HallL-2 (Nexus)

Moderator: Su Hong Kim(Busan Veterans Hospital),Tatsuya Nakama(Tokyo Bay Medical Center)
Panelist: Yo Iwata(Funabashi Municipal Medical Center),Chunshui He(Teaching hospital of Chengdu University of Traditional Chinese Medicine)

[MO-87] The efficacy of HIRANODOME to reduce distal embolization during endovascular therapy for superficial femoral artery disease compared with Filtrap

Tomoya Fukagawa (Saiseikai Yokohama-city Eastern Hospital)

Background

FiltrapR is frequently used for distal protection during endovascular therapy (EVT) for superficial femoral artery (SFA), however, it is sometimes complicated to use. We previously reported simple method of distal protection named HIRANODOME , in which only wrapping TometakunR around the knee to compress the popliteal artery from outside.



Objective

The purpose of the present study is to evaluate the efficacy of HIRANODOME in reducing distal embolization compared with FiltrapR.



Method:

This was a single center retrospective observational study. Between April 2007 and August 2018, patients who underwent EVT for SFA under distal protection were enrolled in this study. We excluded patients with acute limb ischemia and patients using both distal protection methods. Patients were divided into two groups according to the methods of distal protection. Primary endpoint was the incidence of distal embolization.



Results:

In HIRANODOME compared with FiltrapR group, the rate of hemodialysis was lower (8.5% vs. 40.6%; p<0.001), the percentage of in-stent occlusion was higher (61.3% vs. 18.8%; p<0.001), and lesion length was longer (200±94 and 133±120cm; p=0.001). The incidence of distal embolization was similar between two groups (8.5% vs. 12.5%; P=0.50).



Conclusion:

Simple strategy of distal protection named HIRANODOME may be good option to prevent distal embolization.